Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL -2.00% EV-to-EBITDA is -24.70 as of Aug. 12, 2026. The stock has 6 warning signs investors should review. Among 398 Biotechnology companies, Adlai Nortye ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adlai Nortye's enterprise value is $840.68 Mil.
Adlai Nortye's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.04 Mil. Therefore, Adlai Nortye's EV-to-EBITDA for today is -24.70.
The historical rank and industry rank for Adlai Nortye's EV-to-EBITDA or its related term are showing as below:
ANL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.64 Med: -0.53 Max: 1.05
Current: -24.7
During the past 5 years, the highest EV-to-EBITDA of Adlai Nortye was 1.05. The lowest was -25.64. And the median was -0.53.
ANL's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs ANL: -24.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adlai Nortye's PE Ratio (TTM) for today is calculated as:
Adlai Nortye's share price for today is $12.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Adlai Nortye's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's EV-to-EBITDA falls into.
Adlai Nortye's current Enterprise Value is $840.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a EV-to-EBITDA of -24.70 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Adlai Nortye. According to the industry distribution chart, Adlai Nortye ranks #999999 out of 398 companies in the Biotechnology industry.
Is Adlai Nortye's EV-to-EBITDA too high?
Adlai Nortye's current EV-to-EBITDA is -24.70. Based on the distribution chart, Adlai Nortye ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's EV-to-EBITDA compare to REPL and SLDB?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #999999 out of 398 companies for EV-to-EBITDA. This places Adlai Nortye in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Adlai Nortye. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current EV-to-EBITDA is -24.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current EV-to-EBITDA of -24.70. The current EV-to-EBITDA is -24.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Adlai Nortye (ANL), the current EV-to-EBITDA is -24.70 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
